Inhaled biologics Market Outlook 2026–2036: Growth Drivers, Key Companies, Strategic Developments & Adoption Forecast — A Meticulous Next™ Foresight Brief

This Meticulous Next™ brief examines inhaled biologics, meaning proteins, peptides, antibodies, enzymes and vaccines delivered to the airways as dry powder or by nebuliser in place of injection. It tests whether inhaled delivery moves beyond a few approved products into antibodies and chronic respiratory disease, and which participants capture value among biologic developers, large pharmaceutical companies and device makers.

The base of approved products is small. A review published in Drugs in June 2026 counted five inhaled biologics approved for respiratory disease as of 2025, two by the US FDA and one each by regulators in Japan, China and India, including dornase alfa for cystic fibrosis, sargramostim for autoimmune pulmonary alveolar proteinosis in Japan and an inhaled COVID-19 vaccine from CanSino Biologics. The first inhaled insulin, Exubera, was withdrawn about a year after launch. The conclusion is that inhaled delivery works for enzymes, hormones and vaccines, and the commercial record is mixed.

The strongest recent signal is the expansion of inhaled insulin. MannKind received an updated label for Afrezza in January 2026 with starting dose guidance for adults with type 1 diabetes switching from injections, and on 29 May 2026 the FDA approved Afrezza for paediatric patients with type 1 or type 2 diabetes. In the 230-patient INHALE-1 trial the intent-to-treat analysis did not show non-inferiority on HbA1c against multiple daily injections, while per-protocol and sensitivity analyses did, with no effect on lung function. The conclusion is that an inhaled biologic can reach children, and uptake depends on dosing confidence.

Mid-stage antibody programmes show attrition. The Drugs review reports that Novartis has no further studies planned for its inhaled anti-TSLP fragment after a safe phase 2 asthma study, that an AstraZeneca and Pieris anticalin was halted after a non-clinical toxicology finding, and that a phase 3 trial of inhaled interferon beta from Synairgen missed its endpoints in 623 patients. The conclusion is that clinical proof in asthma and COPD is still ahead, and the pipeline will narrow before it grows.

The brief treats inhaled biologics as an emerging signal with a ten year horizon to 2036. It identifies which molecules, regions and developers scale first and what each means for biologic developers, large pharmaceutical companies and device makers. It is a focused 106-page decision brief that presents an indicative trajectory rather than a segmented market model.

Inhaled biologics are large molecules such as proteins, peptides, antibodies and enzymes that are delivered into the lungs as a dry powder or a nebulised mist, either to treat lung disease directly or to enter the blood.

Dry powder products are engineered particles, such as the Technosphere particles used for inhaled insulin, delivered by a portable inhaler. Nebulised products are liquid formulations delivered by a jet or mesh device.

Performance depends on how much drug reaches the lung, the stability of the protein, dose accuracy and the safety of repeated exposure.

Uses are cystic fibrosis, pulmonary alveolar proteinosis, diabetes, respiratory infection, asthma and COPD.

The limits are discontinued programmes, lung safety warnings on some products and uncertainty about dosing compared with injections. The period turns on clinical proof for inhaled antibodies.

The inhaled biologics market, covering proteins, peptides, antibodies, enzymes and vaccines delivered to the airways by dry powder inhaler or nebuliser, and excluding small molecule inhalers, nasal sprays and injected biologics, is valued at USD 0.8–1.2 billion in 2026 and is projected to reach USD 4.19–6.28 billion by 2036, at a CAGR of 18%.

The 2026 base rests on sales of dornase alfa, inhaled insulin, sargramostim and an inhaled vaccine. Growth then follows label expansion of inhaled insulin, the first approvals of inhaled antibodies and fragments, and use in chronic respiratory disease.

The forecast is sensitive to phase 2 and 3 results, device performance and prescribing patterns. Regionally, North America holds the largest base through inhaled insulin and enzymes, Asia-Pacific adds products approved in Japan and China, and Europe grows through clinical programmes.

The base case assumes inhaled insulin grows through paediatric use and the first inhaled antibodies are approved by 2031. An accelerated case assumes positive phase 3 results in asthma or COPD, bringing the inflection to 2029 and lifting the 2036 value to the top of the range. A delayed case assumes further programme discontinuations and slow prescribing, holding growth at the bottom of the range.

Growth drivers

• Preference for needle-free treatment.
• Label expansion of approved products.
• Local lung delivery for respiratory disease.
• Clinical results in children.

Enablers

• Device and formulation partnerships.
• Regulatory guidance for combination products.
• Patient advocacy groups.
• Academic and hospital research.

Restraints and barriers

• Discontinued programmes.
• Lung safety warnings.
• Dosing uncertainty compared with injections.
• Limited prescribing.

The direction of inhaled biologics is set by demand for needle-free delivery, local delivery to the lung, advances in dry powder and nebuliser devices, paediatric and chronic disease use, and programme attrition and safety.

The key participants in inhaled biologics include MannKind Corporation, F. Hoffmann-La Roche Ltd, Novartis AG, AstraZeneca PLC, Sanofi, Synairgen plc, Kamada Ltd., Ansun Biopharma, Inc., Huahui Health Ltd., CanSino Biologics Inc., Partner Therapeutics, Inc., Nobelpharma Co., Ltd., Protalix BioTherapeutics, Inc., Philip Morris International Inc., PARI Pharma GmbH, AptarGroup, Inc., Aerogen Limited, Pulmatrix, Inc., Cipla Limited, Recipharm AB, Pieris Pharmaceuticals, Inc., University of Colorado, Jaeb Center for Health Research, Monash University, University of Sydney, University of Nottingham, Imperial College London, U.S. Food and Drug Administration, European Medicines Agency, Pharmaceuticals and Medical Devices Agency, National Medical Products Administration, Central Drugs Standard Control Organisation, National Institutes of Health, International Society for Pediatric and Adolescent Diabetes, Breakthrough T1D, American Diabetes Association, Cystic Fibrosis Foundation, Cystic Fibrosis Trust and American Lung Association.

The brief profiles representative participants in each archetype and assesses which are positioned to lead as inhaled antibodies reach the clinic.

MannKind leads on inhaled insulin, Roche leads on inhaled enzymes, and Novartis, AstraZeneca and Sanofi lead among large companies with inhaled antibody programmes. Competitive intensity is low in inhaled biologics and rising as large companies return to the route.

Where value migrates.

In 2026 value sits with developers of approved inhaled products, because few products exist and each label expansion adds patients. By 2031 it moves toward developers with approved antibodies and fragments, because chronic respiratory disease is a far larger population. By 2036 it settles in platforms that combine a biologic with a matched device and clinical data. Margins hold for developers with approved products and device know-how and narrow for those reliant on a single early programme.

The signals converge on label expansion and attrition. A paediatric approval for inhaled insulin in May 2026 and a label update in January 2026 support growth, while discontinued antibody programmes, safety warnings and dosing uncertainty limit the pace.

Structural limits show where progress could slow: discontinued programmes, lung safety warnings, dosing uncertainty compared with injections and limited prescribing. The brief therefore tracks four indicators: approvals, trial starts, prescriptions and programme discontinuations.

Insulin and enzymes first, then vaccines and interferons, then antibodies and fragments are the expected order of adoption.